The presentation will be made by
Details of the presentation are as follows: Title: Results of a Phase 1 Study Using the Integrin Antagonist THR-687 in Patients with DME
Date/Time:
Session title: Diabetes, Uveitis, and Retinal Degenerations
Contact:
Tel: +32 16 75 13 10
About
THR-149, a plasma kallikrein inhibitor being developed as a potential new standard of care for DME patients who respond sub-optimally to anti-VEGF therapy. THR-149 has shown positive topline Phase 1 results for the treatment of DME.
The Company is currently preparing to conduct a Phase 2 clinical program, which is expected to start in H1 2020. THR-149 was developed in conjunction with
THR-687, is a pan-RGD integrin inhibitor, that is being developed as a potential new standard of care for all DME patients
Positive topline results in a Phase 1 clinical study assessing it as a treatment for DME were announced in
Important information about forward-looking statements
Certain statements in this press release may be considered 'forward-looking'. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forwardlooking statements will materialize and does not assume an obligation to update or revise any forwardlooking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of
(C) 2020 Electronic News Publishing, source